Skip to main content

Table 1 Characteristics of women with incident breast cancer in Sweden April 1, 2005 to December 31, 2009

From: Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden

Characteristic

Breast cancer patients N (%)

Breast cancer deaths N (%)

Total number

27426

1661 (6.1)

Follow-up time, years, median (range)

2.57 (0–5.25)

1.48 (0–4.50)

Age at diagnosis, years

  

 20-29

104 (0.4)

11 (10.6)

 30-39

1042 (3.8)

73 (7.0)

 40-49

4098 (14.9)

175 (4.3)

 50-59

6259 (22.8)

283 (4.5)

 60-69

7869 (28.7)

329 (4.2)

 70-79

4441 (16.2)

323 (7.3)

 80-89

3037 (11.1)

370 (12.2)

 90≤

576 (2.1)

97 (16.8)

 Median (range)

62 (20–102)

68 (21–102)

Calendar year of diagnosis

  

 2005

4267 (15.6)

451 (10.6)

 2006

5769 (21.0)

477 (8.3)

 2007

5721 (20.9)

359 (6.3)

 2008

5829 (21.3)

250 (4.3)

 2009

5840 (21.3)

124 (2.1)

Stage

  

 I

12645 (46.1)

158 (9.5)

 II

9715 (35.4)

670 (40.3)

 III

1381 (5.0)

316 (19.0)

 IV

438 (1.7)

227 (13.7)

 Missing

3247 (11.8)

290 (17.5)

Severe comorbidity

  

 Disorders associated, with use of ASA*

2334 (8.5)

362 (15.5)

 Disorders associated, with decreased use of ASA**

1116 (4.1)

182 (16.3)

  1. *Hospitalizations or specialized outpatient visits for chronic inflammatory, cardiovascular or cerebrovascular disorders.
  2. **Hospitalizations or specialized outpatient visits for asthma, peptic ulcers, chronic liver disease or venuous thromboembolism.